- Home
- TVTX
as 05-09-2025 12:45pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.7B | IPO Year: | N/A |
| Target Price: | $33.31 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.01 - $25.29 | Next Earning Date: | 05-01-2025 |
| Revenue: | $273,533,000 | Revenue Growth: | 75.65% |
| Revenue Growth (this year): | 68.31% | Revenue Growth (next year): | 55.65% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | May 2 '25 | Sell | $21.05 | 1,771 | $37,279.55 | 128,215 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | May 2 '25 | Sell | $21.05 | 1,784 | $37,553.20 | 93,126 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Apr 11 '25 | Sell | $13.14 | 48 | $630.94 | 93,126 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Feb 11 '25 | Sell | $24.04 | 11,375 | $273,455.00 | 419,173 | |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Feb 11 '25 | Sell | $25.00 | 54,244 | $1,356,100.00 | 63,654 | |
| ROTE WILLIAM E. | TVTX | SENIOR VICE PRESIDENT, R&D | Feb 10 '25 | Sell | $23.53 | 5,200 | $122,356.00 | 98,519 | |
| REED ELIZABETH E | TVTX | SVP, GC & CORPORATE SECRETARY | Feb 10 '25 | Sell | $23.53 | 8,000 | $188,240.00 | 89,482 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Feb 10 '25 | Sell | $24.27 | 5,642 | $137,275.55 | 128,215 | |
| Inrig Jula | TVTX | CHIEF MEDICAL OFFICER | Feb 10 '25 | Sell | $23.53 | 2,568 | $60,425.55 | 89,602 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Travere Therapeutics to Participate at Upcoming Investor Conferences
Simply Wall St.
5 days ago
Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report
Business Wire
8 days ago
Travere Therapeutics Reports First Quarter 2025 Financial Results
Business Wire
10 days ago
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
PR Newswire
10 days ago
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
Business Wire
15 days ago
Travere Therapeutics to Report First Quarter 2025 Financial Results
Simply Wall St.
16 days ago
Exploring 3 High Growth Tech Stocks In The US Market
TipRanks
a month ago
Travere Therapeutics price target lowered to $30 from $32 at Scotiabank
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.